Toxicology and cancer researchers struggle to find cell models with high physiological relevance and the ability to be run in an assay over and over again without introducing variability. To fulfill this need, ATCC scientists have differentiated induced pluripotent stem cells (iPSCs) into widely used cells such as mesenchymal stem cells, CD34+ cells, and monocytes. They may be used to build physiologically relevant cell-based assays for drug development in fields such as regenerative medicine, hematology, oncology, and toxicology.
- Can be terminally differentiated into your desired cell type
- Ideal for cell-based assay development
- Provides a virtually unlimited source of cells
- Eliminates donor variability
- Offers high interexperimental reproducibility
- Predictive of the in vivo situation
It is critical that the standards and model organisms used in toxicological testing are reliable and authenticated. ATCC has the credible models needed to perform standardized, reliable, and reproducible toxicology studies.
While it's recommended to use application specific formulations to grow your iPSCs, ATCC can provide high quality basics such as RPMI, EMEM, and FBS to ensure the success of your experiments.
Need an affordable solution to deriving primary cells from iPSCs? Is CRISPR/Cas9 gene editing, next-generation model development, nucleic acid extractions, or cell provisioning & authentication in your workflow? ATCC can help with customized services and solutions to meet your specific assay development needs.